Current Report Filing (8-k)
November 08 2019 - 5:28PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 7, 2019
PHARMACYTE
BIOTECH, INC.
(Exact Name of Registrant as Specified in
its Charter)
Nevada
|
333-68008
|
62-1772151
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
23046 Avenida de la Carlota, Suite 600
Laguna Hills, CA
|
92653
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant's telephone number, including
area code: (917) 595-2850
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[_] Written communications pursuant to Rule 425 under the Securities
Act
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act
[_] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act
[_] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of exchange on which registered
|
N/A
|
|
N/A
|
|
N/A
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the
Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company [_]
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. [_]
Item 5.03 Amendments to Articles of
Incorporation or Bylaws; Change in Fiscal Year.
On November 7, 2019, PharmaCyte Biotech, Inc. (“Company”)
received confirmation of filing of a Certificate of Amendment to Articles of Incorporation (“Amendment”) from the Office
of the Secretary of State of the State of Nevada. The Amendment increased the number of authorized capital stock from 1,500,000,000
shares to 2,500,000,000 shares, of which 2,490,000,000 shares are common stock, with a par value of $0.0001, and 10,000,000 shares
are preferred stock, with a par value of $0.0001. The effective date of the Amendment is October 31, 2019.
The foregoing description of the Amendment
is qualified in its entirety by reference to the complete terms and conditions of the Certificate of Amendment to Articles of
Incorporation, a copy of which is attached to this Current Report on Form 8-K as Exhibit 3.1 and is incorporated by reference
into this Item 5.03.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: November 8, 2019
|
PHARMACYTE BIOTECH, INC.
|
|
|
|
By:
|
/s/ Kenneth L. Waggoner
|
|
|
Kenneth L. Waggoner
Chief Executive Officer, President and General Counsel
|